A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

Study Number

3772923

Phase

Age Group

Adult

Principal Investigator

Purpose

The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.

Check your eligibility for this trial

Check now

Full Title

A Phase 1 study of JNJ-86974680, an A2a receptor antagonist, administered as monotherapy and in combination with cetrelimab and radiotherapy for advanced non-small cell lung cancer

ClinicalTrials.Gov ID

NCT06116786

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.